Platelet miR‐28 expression level and thrombocytosis in <scp>MPN</scp> patients

Stolyar, M. A.; Gorbenko, A. S.; Olkhovskiy, I. A.

doi:10.1111/ijlh.12951

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Platelet Rnas In Tumor Progressionmentioning

confidence: 99%

“…[89] Furthermore, a negative correlation was found between miR-28 expression and platelet count in myeloproliferative neoplasms, which may be due to the dysregulated interaction between miR-28 and the mRNA of the myeloproliferative leukemia virus oncogene during the proliferative stage of megakaryocytopoiesis. [90] In particular, the role of PMP-delivered miRNAs in tumor progression has attracted considerable attention. PMP can initiate robust capillary-like structure formation in human umbilical vein endothelial cells by directly targeting anti-angiogenic TSP-1 mRNA with Let-7a.…”

Section: Platelet Rnas In Tumor Progressionmentioning

confidence: 99%

See 1 more Smart Citation

A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives

Xiang

Xiang²,

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

Recent years have witnessed a growing body of evidence suggesting that platelets are involved in several stages of the metastatic process via direct or indirect interactions with cancer cells, contributing to the progression of neoplastic malignancies. Cancer cells can dynamically exchange components with platelets in and out of blood vessels, and directly phagocytose platelets to hijack their proteome, transcriptome, and secretome, or be remotely regulated by metabolites or microparticles released by platelets, resulting in phenotypic, genetic, and functional modifications. Moreover, platelet interactions with stromal and immune cells in the tumor microenvironment lead to alterations in their components, including the ribonucleic acid (RNA) profile, and complicate the impact of platelets on cancers. A deeper understanding of the roles of platelets and their RNAs in cancer will contribute to the development of anticancer strategies and the optimization of clinical management. Encouragingly, advances in high-throughput sequencing, bioinformatics data analysis, and machine learning have allowed scientists to explore the potential of platelet RNAs for cancer diagnosis, prognosis, and guiding treatment. However, the clinical application of this technique remains controversial and requires larger, multicenter studies with standardized protocols. Here, we integrate the latest evidence to provide a broader insight into the role of platelets in cancer progression and management, and propose standardized recommendations for the clinical utility of platelet RNAs to facilitate translation and benefit patients.

show abstract

Section: Platelet Rnas In Tumor Progressionmentioning

confidence: 99%

Section: Platelet Rnas In Tumor Progressionmentioning

confidence: 99%

A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives

Xiang

Xiang²,

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

“…Platelets are the primary clinical and pathophysiologic tissue in ET; therefore, platelet miRNA profiling has significance in the understanding of platelet biogenesis and activation in ET. Regarding ET, few studies have identified the significantly dysregulated miRNA signature of platelets in comparison with that of healthy controls [12, 13]. However, as there are other conditions that can result in thrombocytosis, studies comparing the miRNA signatures of ET to that of non-ET thrombocytosis (i.e., reactive thrombocytosis; RT) may identify the key pathways in ET.…”

Section: Introductionmentioning

confidence: 99%

Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia

et al. 2020

View full text Add to dashboard Cite

Differentiating the aetiology of thrombocytosis is limited yet crucial in patients with essential thrombocythaemia (ET). MicroRNAs (miRNAs) regulate haematopoiesis and lineage commitment; aberrant expression of miRNAs plays an important role in myeloproliferative neoplasms. However, the miRNA profile has been poorly explored in ET patients compared to patients with reactive thrombocytosis (RT). A total of 9 samples, including 5 ET patient samples, 2 RT patient samples, and 2 healthy control samples, were analysed in this study. We produced 81.43 million reads from transcripts and 59.60 million reads from small RNAs. We generated a comprehensive miRNA-mRNA regulatory network and identified unique 14 miRNA expression patterns associated with ET. Among the 14 miRNAs, miR-1268a was downregulated in ET and showed an inverse correlation with its 8 putative target genes, including genes associated with thrombus formation and platelet activation (<i>CDH6, EHD2, FUT1, KIF26A, LINC00346, PTPRN, SERF1A,</i> and <i>SLC6A9</i>). Principal component analysis (PCA) showed ET and non-ET groups well clustered in space, suggesting each group had a distinctive expression pattern of mRNAs and miRNAs. These results suggest that the significant dysregulation of miR-1268a and its 8 target genes could be a unique expression of platelet miRNAs and miRNA/mRNA regulatory network in ET patients.

show abstract

The use of platelets as a clinical tool in oncology: opportunities and challenges

Bravaccini,

Boldrin,

Gurioli

et al. 2024

Cancer Letters

View full text Add to dashboard Cite

Platelet miR‐28 expression level and thrombocytosis in MPN patients

Cited by 4 publications

References 11 publications

A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives

A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives

Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia

The use of platelets as a clinical tool in oncology: opportunities and challenges

Contact Info

Product

Resources

About